Active Investments

Aeglea Biotherapeutics

Private

Audentes Therapeutics

Private

AveXis

Private

REGENXBIO

Private

Replicor

Private

Avalanche Biotech

Public (NASDAQ: AAVL)

Juno Therapeutics

Public (NASDAQ: JUNO)

BioCryst Pharmaceuticals

Public (NASDAQ: BCRX)

DBV Technologies

Public (NYSE: DBV)

Ocera Therapeutics

Public (NASDAQ: OCRX)

Alumni Investments

Ardea Biosciences

Acquired by AstraZeneca

Dyax

Public (NASDAQ: DYAX)

Keryx Biopharmaceuticals

Public (NASDAQ: KERX)

Medivation

Public (NASDAQ: MDVN)

Neurocrine Biosciences

Public (NASDAQ: NBIX)

NPS Pharmaceuticals

Public (NASDAQ: NPSP)

Vanda Pharmaceuticals

Public (NASDAQ: VNDA)

YM Biosciences

Acquired by Gilead

Bong Koh Partner

Focus Areas: Biotechnology
Location: New York

Bong originally joined Venrock in 2009 and has been doing public and private investing since 2004. He did his medical training at Harvard’s Mass Eye & Ear Infirmary (ophthalmology), Stanford Hospital (internal medicine) and UCSF (pathology).

Bong is a manager of Venrock’s public and cross-over biotech fund, Venrock Healthcare Partners, where he provides leadership in biotech investments.

On the private side, Bong led Venrock’s investments in Aeglea Biotherapeutics, Avalanche Biotechnologies (series B), Audentes Therapeutics (series B), AveXis (pre-mezzanine), Juno Therapeutics (series A), REGENXBIO (series C & D) and Replicor (first institutional investor round).

Bong is on the AveXis’ board of directors and is an observer at REGENXBIO Inc. and Audentes Therapeutics.

Bong earned his B.A. from Yale University, his M.D. from the University of California, San Francisco, and an M.B.A. from Harvard Business School.

Active Companies

Aeglea Biotherapeutics

Aeglea was founded in December of 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin.

Audentes Therapeutics

Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of gene therapy technology.

AveXis

A leading gene therapy company developing treatments for rare and life-threatening genetic diseases.

REGENXBIO

REGENXBIO is the leading next-generation AAV gene therapy company, developing a new class of personalized therapies based on its proprietary NAV® Technology platform for a range of severe diseases with serious unmet needs.

Replicor

A biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection.

Avalanche Biotech

Juno Therapeutics

BioCryst Pharmaceuticals

DBV Technologies

Ocera Therapeutics

Alumni Companies

Ardea Biosciences

Dyax

Keryx Biopharmaceuticals

Medivation

Neurocrine Biosciences

NPS Pharmaceuticals

Vanda Pharmaceuticals

YM Biosciences